AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04135781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin（130mg/m2 , iv, d1）
Study NCT04863560 — intervention group
Intervention type: OTHER
Intervention: Visual Cueing
Description: Lines on the floor to step over
Study NCT03209713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Education
Description: A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
Study NCT03209713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Reminder
Description: Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
Study NCT05264493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaxRedy ™
Description: 5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
Study NCT05264493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Hydrochloride Injection, USP
Description: 2 mg IM (2mg/2 mL) injection into gluteal muscle
Study NCT04863560 — intervention group
Intervention type: OTHER
Intervention: tactile Cueing
Description: Vibration to step in time with (metronome like)
Study NCT02278757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
Study NCT02278757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low protein diet
Description: Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
Study NCT02457286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
Study NCT02457286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
Study NCT04443790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin Human
Study NCT04443790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leptin Human
Study NCT01220635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions Program
Description: Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
Study NCT01220635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Support Program
Description: Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
Study NCT00987740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolung Respiratory Assist System
Description: Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
Study NCT01877317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfFit adjusted hearing device
Description: Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
Study NCT02355418 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve repair
Description: Standard mitral valve repair surgery
Study NCT05264493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Hydrochloride Injection, USP
Description: 2 mg bolus IV (2mg/2 mL)
Study NCT03646240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
Study NCT04135781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capetabine（1000 mg/m2 po, d1-14 bid ）
Study NCT01875861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Quality Improvement Plus Facilitation
Description: The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
Study NCT00810641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gufoni maneuver
Description: For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
Study NCT00810641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head-shaking maneuver
Description: For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
Study NCT04937439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy program
Description: 1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting
Study NCT04937439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy program
Description: 1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting
Study NCT04937439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental trunk training A
Description: Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
Study NCT04937439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental trunk training B
Description: Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
Study NCT04937439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental trunk training C
Description: Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
Study NCT02885909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTINUE GLUCOSE MONITOR
Description: Continue glucose monitor
Study NCT02885909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin protocal
Description: Using insulin protocal based on glucose monitor
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting dose 15 mg/ m2 by vein on Day -11.
Study NCT04108767 — intervention group
Intervention type: BEHAVIORAL
Intervention: Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors
Description: The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 1000 mg by vein on Day -11 through Day -2.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on Days -3 and -2.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -11 AM to Day -2 PM.
Study NCT01983969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -9.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1.
Study NCT01983969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Days -9.
Study NCT03771469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep study
Description: Sleep study
Study NCT03835689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families Intervention (formerly Family Help)
Description: Distance HEALTH education intervention focused on skill learning for parents
Study NCT04654143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVL-GSK098 capsule, placebo
Description: Oral QD
Study NCT03110848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg daily
Study NCT03110848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
Study NCT03110848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
Study NCT02588339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
Study NCT02588339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
Study NCT02588339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
Study NCT01385163 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Standard psychosocial counseling
Study NCT01385163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Savings/Loans Assoc
Description: economic intervention for group savings and loans
Study NCT01385163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: group 12 session intervention
Study NCT03076437 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs and Anti-CD19-CAR transduced T cells
Description: Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine).
Study NCT02709018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: Angiotensin receptor blocker (ARB)
Study NCT02709018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02709057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
Study NCT01163422 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantation of 3-chamber pacemaker
Description: Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
Study NCT01163422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of 3-chamber pacemaker
Description: Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
Study NCT01826214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
Study NCT04267757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectovaginal fistula repair with Martius flap
Description: rectovaginal fistula repair with Martius flap
Study NCT02457286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan device (Echosens)
Description: This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
Study NCT03053830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
Study NCT01277068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical and medical procedures
Description: this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
Study NCT02781194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Bair Hugger™
Description: forced-air warming blanket
Study NCT02781194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P HumiGard™ Surgical Humidification System
Description: warmed, humidified insufflation
Study NCT00810745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: starr
Description: stapled transanal rectal resection
Study NCT02264977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Study NCT02770222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Study NCT04938674 — intervention group
Intervention type: DEVICE
Intervention: ultrasonic guidance
Description: Standard process for blood collection using Ultrasonic Guided puncture
Study NCT00810641 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham maneuver
Description: For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
Study NCT01843075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Daily subcutaneous injection
Study NCT03313193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure for Children in Treatment for a Childhood Cancer
Description: This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
Study NCT02770222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
Study NCT02770222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
Study NCT02343796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibreglass reinforced composite restoration-everStick
Description: For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
Study NCT02343796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everStick
Description: GC, Belgium